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Summary
Release of granulysin by cd T cells contributes to tumour cell killing. A
cytolytic 9000 MW isoform of granulysin kills tumour cells directly,
whereas a 15 000 MW precursor has been hypothesized to cause both the
maturation and migration of dendritic cell (DC) populations. Recruiting
DC to a tumour is beneficial as these cells initiate adaptive immune
responses, which contribute to the eradication of malignancies. In this
study, Vd2+ cd T cells were activated by stimulation of peripheral blood
mononuclear cells with zoledronic acid or Bacillus Calmette–Guerin
(BCG), or were isolated and cultured with tumour targets. Although a
large proportion of resting Vd2+ cd T cells expressed 15 000 MW gran-
ulysin, 9000 MW granulysin expression was induced only after stimula-
tion with BCG. Increased levels of activation and granulysin secretion
were also observed when Vd2+ cd T cells were cultured with the human
B-cell lymphoma line Daudi. High concentrations of recombinant 15 000
MW granulysin caused migration and maturation of immature DC, and
also initiated fugetaxis in mature DC. Conversely, low concentrations of
recombinant 15 000 MW granulysin resulted in migration of mature DC,
but not immature DC. Our data therefore support the hypothesis that
Vd2+ cd T cells can release granulysin, which may modulate recruitment
of DC, initiating adaptive immune responses.
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Introduction
A small subset of T cells possess a T-cell receptor com-
posed of c and d chains rather than a and b chains,
and these cd T cells account for up to 5% of the T
cells found within human peripheral blood.1 Although
the proportion of cd T cells in the T-cell population as
a whole is low, this subset does not require processing
and presentation of antigen to become activated, allow-
ing a rapid response to infected or malignant target
cells.
Previous research has shown evidence that cd T cells
bearing a Vd2 chain, comprising approximately 80% of
the cd T-cell population found in the peripheral blood
of humans,2 are capable of recognizing phosphoantigens
such as prenyl pyrophosphates. These are intermediates
of the isoprenoid synthesis pathways, present within both
bacteria and eukaryotes. Within bacteria, the phospho-
antigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophos-
phate (HMBPP) is produced in the 2-C-methyl-D-
erythritol-4-phosphate pathway, and its eukaryotic
homologue isopentenyl pyrophosphate (IPP) is produced
Abbreviations: BCG, Bacillus Calmette–Guerin; DC, dendritic cell; FSC, forward scatter; HLA-DR, human leucocyte antigen-D-
related; HMBPP, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate; IPP, isopentenyl pyrophosphate; MACS, magnetic activated
cell sorting; PBMC, peripheral blood mononuclear cells; SDF-1, stromal cell derived factor 1; SSC, side scatter; ZA, zoledronic
acid
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in the mevalonate pathway.3 Research has shown that
Vd2+ cd T cells are activated by cells that accumulate
HMBPP and/or IPP.4 Although the exact mechanism by
which these cells recognize phosphoantigens remains to
be fully elucidated, the current hypothesis suggests that
intracellular binding of phosphoantigens to the molecule
butyrophilin 3A1 is involved.5–7 HMBPP has been found
to be substantially more stimulatory than IPP to Vd2+
cd T cells, allowing these cells to easily differentiate for-
eign bacteria from self cells.8 Although the level of IPP
within healthy eukaryotic cells is not usually sufficient to
cause activation of Vd2+ cd T cells, this molecule is
overexpressed in some tumours in which the mevalonate
pathway is dysregulated.9 Additionally, nitrogen-contain-
ing bisphosphonate drugs such as zoledronic acid (ZA)
can artificially elevate the level of IPP within cells,
because of their inhibition of enzymes involved in the
mevalonate pathway, resulting in an accumulation of
IPP within the cell.10
Granulysin is a cytotoxic effector molecule, used by
several immune cell populations to kill pathogens, in
addition to infected or transformed cells. cd T-cell expres-
sion of this molecule has been shown to be pivotal in the
immune response to both Mycobacterium tuberculosis and
Plasmodium falciparum, as well as in several types of
tumour.11–13 The 9000 MW isoform of granulysin has
been shown to be directly cytotoxic, and co-localizes with
other cytotoxic molecules such as granzymes.14,15 Evi-
dence suggests that the 15 000 MW full-length isoform,
initially thought of as an inert precursor, could also have
distinct immune functions. The 15 000 MW granulysin
localizes to lysosome-related effector vesicles,15 and has
been shown to cause the maturation of immature DC
populations, and the migration of both immature and
mature DC, in addition to monocytes, memory ab T cells
and natural killer (NK) cells.16–19
In this paper, we show that Vd2+ cd T cells are cap-
able of secreting granulysin in response to tumour. In
addition, we show that recombinant 15 000 MW gran-
ulysin can cause the migration and maturation of DC,
and propose that 15 000 MW granulysin has a dual
migratory function; we found that immature DC
migrate towards high concentrations of 15 000 MW
granulysin, whereas mature DC migrated only towards
low concentrations of this molecule, and in fact
migrated away from higher concentrations of 15 000
MW granulysin. This suggests the ability of 15 000
MW granulysin to induce both chemotaxis and fuge-
taxis of DC, in a concentration-dependent manner and
depending on DC maturation status. We therefore pro-
pose that the degranulation of Vd2+ cd T cells in
response to tumour can recruit and mature DC, leading
to the initiation of an adaptive immune response to
tumour antigens.
Materials and methods
Peripheral blood mononuclear cell isolation
Whole blood samples taken from healthy donors were
sourced from anonymized leucocyte blood cones supplied
by the UK Blood Transfusion Service, London, UK or
were collected from consenting healthy volunteers at St
George’s, University of London, Tooting, UK. Peripheral
blood mononuclear cells (PBMC) were isolated from
whole blood samples by density-adjusted centrifugation
using Histopaque 1077 (Sigma-Aldrich, Dorset, UK).
Residual red blood cells were removed through addition
of ammonium–chloride–potassium lysing buffer (Thermo
Fisher Scientific, Waltham, MA), and contaminating pla-
telets were eliminated by three slow-speed centrifugations
(200 g, 10 min), in RPMI-1640 medium (Sigma-Aldrich).
Finally, PBMC were resuspended in freezing medium
[composed of 45% (volume/volume; v/v) RPMI-1640
medium, 45% (v/v) fetal buffered saline and 10% (v/v)
dimethylsulphoxide; all Sigma-Aldrich] and initially fro-
zen at 80°, before being transferred to liquid nitrogen
for extended storage.
Cell isolation
CD14+ monocytes and cd T cells were isolated from
PBMC using magnetic activated cell sorting (MACS). In
order to isolate cd T cells, non-cd T cells (ab T cells, NK
cells, monocytes, B cells, DC, stem cells, granulocytes and
erythroid cells) were depleted from PBMC using a c/d+ T
Cell Isolation kit from Miltenyi Biotec (Bergisch Glad-
bach, Germany). Monocytes were isolated through posi-
tive selection of CD14+ cells using CD14 microbeads
from Miltenyi Biotec. The purity of each isolated cell
population was assessed by flow cytometry, and was
>90% for cd T-cell populations and >95% for monocyte
populations.
Cell cultures
All cells were cultured in RPMI-1640 medium (Sigma-
Aldrich) supplemented with 10% (v/v) fetal buffered sal-
ine (Sigma-Aldrich), 10 000 U/ml penicillin and
10 000 µg/ml streptomycin (Thermo Fisher Scientific).
For experiments involving PBMC, 1 9 106 cells were
seeded in 96-well round-bottomed tissue-culture plates
(Corning, Corning, NY) in a total volume of 200 ll sup-
plemented RPMI-1640 medium. The following reagents
were used to stimulate cells as required: 10 lg/ml BCG
(Danish strain 1331; Statens Serum Institut, Copenhagen,
Denmark), 5 lM ZA, 30 ng/ml phorbol 12-myristate 13-
acetate (PMA), and 1 lg/ml ionomycin (all from Sigma-
Aldrich).
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For cd T-cell expansion experiments, 5 9 105 PBMC
were seeded in a total volume of 200 ll supplemented
RPMI-1640 medium in 96-well round-bottomed tissue-
culture plates. Zoledronic acid (5 µM; Sigma-Aldrich) and
15 ng/ml (315 U/ml) interleukin-2 (IL-2) (R&D Systems,
Minneapolis, MN) were added to the medium. Cells were
then cultured for 9 days before isolation of the cd T-cell
population by MACS, and fresh supplemented RPMI-
1640 medium and IL-2 were added every 2–3 days.
Daudi and Raji B-cell lymphoma lines (European Col-
lection of Authenticated Cell Cultures, Salisbury, UK)
were used in experiments as cd T-cell-susceptible and -re-
sistant target cells, respectively. Tumour cells were cul-
tured in 75-cm2 tissue-culture flasks at a recommended
density of 4 9 105 cells/ml in supplemented RPMI-1640
medium (Sigma-Aldrich) and were passaged every 2–
3 days to maintain the recommended cell density.
For co-culture experiments, 5 9 105 expanded and iso-
lated cd T cells/ml and 5 9 105 tumour cells/ml were
added to a total volume of 200 ll supplemented RPMI-
1640 medium in 96-well round-bottomed tissue-culture
plates, at a 1 : 1 ratio of target to effector cells. Cells were
cultured for 24, 48 or 72 hr before being harvested.
DC differentiation and maturation
Isolated peripheral blood CD14+ monocytes were seeded
into six-well flat-bottomed tissue-culture plates at a density
of 1 9 106 cells/ml in a total volume of 3 ml supplemented
RPMI-1640 medium. Then, 100 ng/ml (2900 U/ml) IL-4
and 50 ng/ml (750 U/ml) granulocyte–macrophage colony-
stimulating factor (GM-CSF (both R&D Systems)) were
added to the medium, and cells were cultured for 7 days.
Half of the total volume of medium was replaced every 2–
3 days with fresh medium containing 100 ng/ml (2900 U/
ml) IL-4 and 50 ng/ml (750 U/ml) granulocyte–macrophage
colony-stimulating factor. Following 7 days of culture, light
microscopy and flow cytometry were used to confirm the
differentiation of CD14+ monocyte populations into imma-
ture DC. To test maturation, immature DC were treated for
24 hr with 100 ng/ml recombinant lipopolysaccharide (LPS)
or 66 nM recombinant 15 000 MW granulysin (both R&D
Systems). The purity of recombinant 15 000 MW granulysin
used was determined by the manufacturer to be >95% by
sodium dodecyl sulphate–polyacrylamide gel electrophore-
sis, and endotoxin contamination was assessed to be
<10 EU per 1 lg of the protein by the limulus amoebocyte
lysate method.
Flow cytometry
Cells were washed in flow cytometry buffer [phosphate-
buffered saline supplemented with 1% (weight (w)/v)
bovine serum albumin, 01% (w/v) sodium azide and
05 mM EDTA (all Sigma-Aldrich), and stained with
fluorochrome-conjugated antibodies according to the man-
ufacturer’s instructions. Fc receptor blocking solution was
added to flow cytometry buffer at a ratio of 1 : 20 before
staining, to prevent non-specific binding (BioLegend, San
Diego, CA). Following staining, cells were washed three
times in flow cytometry buffer, before being fixed with 4%
(w/v) paraformaldehyde (BD Biosciences, Oxford, UK).
For experiments involving intracellular staining, 35 lM
brefeldin A (Sigma-Aldrich) was added for the final 3 hr of
culture to block protein trafficking. Following any required
surface staining, cells were simultaneously fixed and perme-
abilized using 4% (w/v) paraformaldehyde and 01% (v/v)
saponin (Cytofix/Cytoperm kit; BD Biosciences) before
staining with fluorochrome-conjugated antibodies, accord-
ing to the manufacturer’s instructions. The following anti-
bodies were used: Alexafluor 488–15 000+ 9 000 MW
granulysin(RB1), phycoerythrin (PE)-CD56(B159), fluo-
rescein isothiocyanate (FITC)-CD8(RPA-T8) (all BD Bio-
sciences), Alexafluor 647–9 000 MW granulysin(DH2), PE-
dazzle-CCR5(J418F1), FITC-CCR7(G043H7), FITC-
CD107a(H4A3), FITC/allophycocyanin (APC)-CD27(M-
T271), Peridinin chlorophyll protein (PerCP)-CD3
(OKT3), FITC/APC-CD45RA(HI100), FITC/APC-CD69
(FN50), PerCP-Cy5.5-CD80(2D-10), Alexafluor 647-hu-
man leucocyte antigen-D-related (HLA-DR) (L243) (all
BioLegend), PE-CD14(T€UK4), APC-Granzyme B
(REA226), PE-Vd1(REA173), PE-Vd2(REA771), PE-cd T-
cell receptor (11F2) (all Miltenyi Biotec). For all experi-
ments, matched isotype controls were used to determine
levels of non-specific binding.
To measure degranulation, anti-CD107a antibodies and
1 lM monensin (Sigma-Aldrich) were added for the final
4 hr of culture, before harvesting cells for staining. To mea-
sure tumour cell death, a live/dead discrimination dye
(Thermo Fisher Scientific) was used, allowing quantifica-
tion of dead Raji or Daudi cells by flow cytometry. The dye
was diluted 100-fold in FACS buffer containing cells to be
stained. The cells were then incubated for 30 min at room
temperature before being stained with a FITC-conjugated
antibody specific for CD19, allowing identification of
tumour cells. Peaks of fluorescence representing live and
dead cells were established before commencement of exper-
iments using viable and heat-killed tumour cells, respec-
tively, and tumour cell death calculated as the percentage
fluorescence observed within each condition, which was
above that previously established to represent live cells.
Stained cells were run on an LSRII flow cytometer (BD
Biosciences), and data were analysed using FACSDIVA (BD
Biosciences) or FLOWJO (FlowJo LLC, Ashland, OR) soft-
ware.
ELISA
The concentrations of granulysin, granzyme B and inter-
feron-c (IFN-c) that were present within co-culture
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supernatants were determined by ELISA (R&D Systems).
The commercial granulysin ELISA could not distinguish
between the 15 000 and 9000 MW isoforms of granulysin,
and as such, data reflect the concentration of total gran-
ulysin only. Briefly, plates were coated with a mouse anti-
human antibody specific for each protein of interest. A
twofold, seven-point serial dilution of each protein was
performed to generate a standard curve, and samples of
unknown concentration were added to the plate. Biotiny-
lated mouse anti-human antibodies specific for each pro-
tein were added, followed by streptavidin–horseradish
peroxidase. Finally, a 1 : 1 solution of hydrogen peroxide
and 3,30,5,50-tetramethylbenzidine was added to plates to
induce a colour change, and the reaction was stopped by
addition of 2 M sulphuric acid. Between each step, plates
were washed three times in wash buffer (005% Tween-20
diluted in phosphate-buffered saline; Sigma-Aldrich). The
final absorbance of each sample was read at 450 nm and
protein concentrations were interpolated from the stan-
dard curve using a four-parameter logistic model pro-
vided by GRAPHPAD PRISM.
Ibidi l-migration assays
Migration of DC populations was assessed using Ibidi l-
migration assays, performed according to the manufac-
turer’s instructions (Ibidi, Martinsried, Germany). In
brief, immature or mature DC were diluted to a concen-
tration of 3 9 106 cells/ml in collagen gel, and added to
the cell chamber of a l-migration slide (Ibidi). Unsupple-
mented medium was added to each chemoattractant
chamber of the l-migration slide, and chemoattractants of
interest (500 ng/ml RANTES, 2 ng/ml CCL19, 10 or
66 nM recombinant 15 000 MW granulysin; all R&D Sys-
tems) were added to one chemoattractant chamber to pro-
duce a concentration gradient across the slide. Migration
was monitored using a time-lapse microscope (Olympus
IX70 inverted system; Olympus Corporation, Tokyo,
Japan) equipped with a Hamamatsu C4742-95 digital
camera and a motorized stage controlled by IMAGE PRO-PLUS
software (Media Cybernetics, Rockwell, MD, USA). The
microscope and stage were enclosed within a heated (37°)
humidified chamber (Solent Scientific, Portsmouth, UK)
at 5% CO2. Images were captured every 15 min over a
period of 24 hr and were then used to analyse the migra-
tion of cells towards each chemoattractant, using IMAGEJ
software (National Institutes of Health, Bethesda, MD).
Statistical analyses
All statistical analyses were carried out using GRAPHPAD
PRISM software (Prism 7; GraphPad Software, San Diego,
CA). Significance was determined using either one-way or
two-way analysis of variance or paired t-tests, assuming
Gaussian distributions in all cases. Unless otherwise sta-
ted, data are presented as mean  standard deviation
(SD). Statistical differences with P-values <005 are
reported in the figures (*, **, *** and **** are used to
report P-values of <005, <001, <0001 and <00001,
respectively).
Results
Granulysin is expressed in Vd1+ and Vd2+ cd T-cell
populations
We first sought to confirm previous evidence that cd T
cells express granulysin when in a resting state.20 We
assessed the intracellular expression of granulysin within
this cell population and compared it to that observed
within NK cells and CD8+ ab T cells, previously shown
to express granulysin constitutively and following an acti-
vation signal, respectively.21,22 We then further separated
the peripheral blood cd T-cell population into Vd1+ and
Vd2+ subpopulations, and assessed the resting state
expression of granulysin in each subpopulation.
Flow cytometry was used to identify each immune cell
population within PBMC preparations (Fig. 1a) and to
determine the frequency of granulysin expression within
these cells. Two antibodies were used to distinguish
between total granulysin (hereafter referred to as
15 000+ 9000 MW granulysin) expression, and 9000 MW
granulysin expression (Fig. 1b). Although the 9000 MW
isoform of granulysin is produced through cleavage of the
15 000 MW precursor and therefore exhibits identical
epitopes, the antibody used here to identify 9000 MW
Figure 1. Resting cd T cells express granulysin. (a) Representative flow cytometry plots depicting the gating strategy used to identify cell popula-
tions of interest from peripheral blood mononuclear cells (PBMC) preparations. Lymphocytes were gated (G1) according to size (forward scatter;
FSC) and granularity (side scatter; SSC). Within gate G1, CD8+ ab T cells, natural killer (NK) cells and cd T cells were further gated on using
established lineage markers for these cells (G2–G4). (b) Following identification of each immune cell population, the percentage of cells express-
ing 15 000+ 9000 MW granulysin or 9000 MW granulysin was determined by flow cytometry (expression within cd T-cell populations depicted).
(c–e) Percentage expression of 15 000+ 9000 MW granulysin, 9000 MW granulysin, and granzyme B within populations of CD8+ ab T cells, NK
cells and cd T cells, as determined by flow cytometry. (f) Gating strategy used to differentiate between Vd1+ cd T cells and Vd2+ cd T cells. (g,h)
Percentage expression of 15 000+ 9000 MW and 9000 MW granulysin within populations of Vd1+ cd T cells and Vd2+ cd T cells as determined
by flow cytometry. Data shown are obtained from between six and ten independent experiments using PBMC from ten individual donors, with
error bars (SD). Differences between groups were assessed by one-way analysis of variance. *P < 005. ***P < 0001 ****P < 00001.
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granulysin has been previously cited in the literature to
have higher affinity for the cleaved 9000 MW granulysin
isoform, compared with the full-length 15 000 MW pre-
cursor 19,23,24
Natural killer cell populations had the highest percent-
age of cells expressing both isoforms of granulysin, and
CD8+ ab T cells had the lowest (Fig. 1c,d). Expression of
granulysin, and granzyme B within cd T-cell populations,
was most similar to that observed within NK cell popula-
tions (Fig. 1e). The percentage of Vd2+ cd T cells found
to be expressing either isoform of granulysin was analo-
gous to that observed within cd T-cell populations as a
whole, whereas very few Vd1+ cd T cells were observed to
express either isoform of granulysin (Fig. 1f–h).
Taken together, these results show that peripheral
blood cd T cells, and in particular those cells expressing a
Vd2 chain, express both isoforms of granulysin when in a
resting state, in a manner most comparable to NK cells of
the innate immune system.
cd T-cell stimuli can increase the expression of
intracellular 9000 MW granulysin
We and others have shown that Vd2+ cd T cells within
PBMC preparations can be activated in response to short-
term treatment with ZA and BCG.25,26 However, the abil-
ity of these stimuli to cause changes to the intracellular
expression of granulysin within this cell population
remains to be determined. We therefore conducted exper-
iments to investigate whether 24 hr of stimulation with
these reagents could cause an increase in the intracellular
expression of granulysin in Vd2+ cd T-cell populations
present within PBMC preparations.
Twenty-four hours of stimulation with ZA or BCG did
not cause any marked expansion of Vd2+ cd T cells within
the PBMC population (not shown). However, an increase in
the expression of activation marker CD69 on this cell popu-
lation was observed, and was comparable to that seen fol-
lowing stimulation with PMA and ionomycin, known to
cause activation of this cell type (Fig. 2a). Activation seen in
response to either ZA or BCG was not observed within pop-
ulations of CD8+ T cells or NK cells (Fig. 2a).
The percentage of Vd2+ cd T cells expressing either
15 000+ 9000 MW granulysin or granzyme B was not
changed in response to ZA or BCG stimulation (Fig. 2b,
c). Interestingly, we observed a statistically significant
increase in the percentage of Vd2+ cd T cells expressing
9000 MW granulysin when PBMC were treated with BCG
for 24 hr (Fig. 2d). A small increase in expression of this
isoform was also observed following stimulation with ZA,
although this was not statistically significant. This increase
in 9000 MW granulysin expression on BCG treatment
was not seen within populations of NK cells or CD8+ ab
T cells (Fig. 2d) or when isolated populations of Vd2+ cd
T cells were stimulated with BCG (Fig. 2e). This suggests
that this response is specific to Vd2+ cd T-cell popula-
tions, and furthermore confirms previous literature sug-
gesting that the involvement of additional immune cell
populations is crucial to BCG-induced stimulation of
Vd2+ cd T-cell populations.26
Taken together, these data show that Vd2+ cd T cells
present within PBMC populations are activated by ZA or
BCG, but only BCG stimulation causes a change in the
expression of intracellular granulysin within this cell pop-
ulation.
Granulysin is released from Vd2+ cd T cells in
response to tumour
We next designed experiments to investigate the release
of granulysin from Vd2+ cd T cells following culture with
tumour cells. Vd2+ cd T cells were isolated from PBMC
pre-treated for 9 days with IL-2 and ZA to induce expan-
sion of the Vd2+ cd T-cell population. Isolation of the
Vd2+ cd T-cell population was achieved using MACS,
and purity was determined by flow cytometry (see Sup-
plementary material, Fig. S1). As expansion of Vd2+ cd T
cells requires prior activation of this cell type through
treatment with ZA, cells were tested for markers of
exhaustion throughout the expansion period to determine
if their use would be feasible in subsequent co-culture
studies. We found an increase in the markers PD-1 and
Lag-3 during the expansion process, but Vd2+ cd T cells
were still capable of secreting granulysin following the 9-
day expansion period, and so were determined to be
viable for use in co-culture studies (Fig. 3a).
Vd2+ cd T cells were cultured with the B-cell lymphoma
lines Daudi and Raji, known to be sensitive and resistant
to Vd2+ cd T-cell killing, respectively.9,27 In addition, Raji
cells were pre-treated for 24 hr with ZA and subsequently
washed before co-culture, to render them more susceptible
to Vd2+ cd T-cell killing.28 Preceding co-culture, the ability
of Daudi cells, Raji cells and Raji cells pre-treated with ZA
to produce the cytotoxic molecules investigated within this
set of experiments was determined, and intracellular stain-
ing showed no expression of 15 000+ 9000 MW gran-
ulysin, 9000 MW granulysin, granzyme B or IFN-c within
these cell populations (not shown). Following 24, 48 and
72 hr of culture, Vd2+ cd T cells and co-culture super-
natants were harvested and used in flow cytometry and
ELISA experiments, respectively.
Our data show that culture with Daudi cells, Raji cells
and Raji cells pre-treated with ZA caused a comparable
increase in the expression of CD69 on Vd2+ cd T cells
when compared with that seen on Vd2+ cd T cells cul-
tured alone. This observation was seen regardless of the
tumour cell line tested, suggesting that Vd2+ cd T cells
are activated by both Daudi and Raji tumour cell lines
(Fig. 3b). Of note, we found that the percentage of Vd2+
cd T cells expressing CD69 was approximately 60% lower
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than that observed when these cells were within a PBMC
preparation (Fig. 2a). This is presumably because the iso-
lated Vd2+ cd T cells had been previously activated by
ZA, during expansion of this cell population within
PBMC preparations before isolation. Interestingly,
although we observed activation of Vd2+ cd T cells in
response to all three tumour cell lines, we found only
very small concentrations of IFN-c within supernatants
taken from co-culture of Vd2+ cd T cells with all tumour
cell lines tested (Fig. 3c).
Culture of Vd2+ cd T cells with tumour cell lines caused
an increase in the percentage of cells expressing CD107a
(Fig. 3d). Although the percentages of Vd2+ cd T cells
expressing CD107a following culture with Daudi cells and
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Figure 2. Stimulation of Vd2+ cd T cells with bacillus Calmette–Guerin (BCG) causes an increase in the intracellular expression of 9000 MW
granulysin. (a–d) The percentage of Vd2+ cd T cells, natural killer (NK) cells and CD8+ T cells expressing early activation marker CD69,
15 000+ 9000 MW granulysin, granzyme B and 9000 MW granulysin following 24 hr of peripheral blood mononuclear cell (PBMC) stimulation
with zoledronic acid (ZA), BCG or phorbol 12-myristate 13-acetate/ionomycin (PMA/I), as determined by flow cytometry. (e) The percentage of
Vd2+ cd T cells expressing 9000 MW granulysin following either 24 hr of PBMC stimulation with BCG, or following isolation of this cell popula-
tion from unstimulated PBMC, and subsequent stimulation of these isolated Vd2+ cd T cells for 24 hr. Data shown are mean values obtained
from six independent experiments using PBMC from six individual donors, with error bars (SD). Statistics refer to the differences between treat-
ment group and untreated group, and were assessed by one-way analysis of variance. ***P < 0001. ****P < 0.0001.
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Raji cells pre-treated with ZA were comparable, CD107a
expression on Vd2+ cd T cells cultured with untreated Raji
cells did not increase significantly above that observed in
untreated cells, suggesting a lack of degranulation in
response to this tumour cell type. Culture of Vd2+ cd T cells
with Daudi tumour cells caused the highest concentrations
of granulysin released into co-culture supernatants (Fig. 3e).
However, contrary to our expectations, we found that the
concentration of granzyme B within co-culture supernatants
did not follow this pattern. Instead, the concentrations of
granzyme B found within co-culture supernatants were
notably lower than the concentrations of granulysin
observed, and in fact, culture of Vd2+ cd T cells with Daudi
cells actually produced the lowest concentrations of gran-
zyme B present within co-culture supernatants (Fig. 3f).
The peak in granulysin release from Vd2+ cd T cells cultured
with Daudi cells was observed following 48 hr of culture,
and correlated with the time-point at which the maximal
killing of Daudi cells (793  133%) was observed
(Fig. 3g). Culture of Vd2+ cd T cells with untreated Raji cells
did not induce any secretion of granulysin above that pro-
duced by Vd2+ cd T cells cultured alone, and also did not
result in any marked increase in tumour cell death. Interest-
ingly, although culture of Vd2+ cd T cells with Raji cells pre-
treated with ZA did not appear to result in increased gran-
ulysin secretion in comparison to culture with untreated
Raji cells, there was a substantial increase in killing of Raji
cells pre-treated with ZA following 24 hr of culture. This
suggests that treating this cell line with ZA did result in
some sensitization to Vd2+ cd T-cell killing.
Taken together, these data suggest that Vd2+ cd T cells
are activated by tumour cells, subsequently resulting in
degranulation, granulysin release and cell death. However,
this appears to occur without concomitant IFN-c and
granzyme B release.
Recombinant 15 000 MW granulysin can induce a
mature phenotype in DC
Previous studies have shown the ability of recombinant
15 000 MW granulysin to cause maturation of immature
DC,17,19 and we sought here to replicate these findings.
Immature DC were differentiated from isolated popula-
tions of peripheral blood CD14+ monocytes (see Supple-
mentary material, Fig. S2), before being cultured for
24 hr in the presence of recombinant 15 000 MW gran-
ulysin. Culture of immature DC with LPS was used as a
positive control of maturation, whereas medium alone
was used as a negative control, and had no effect on mat-
uration (Fig. 4). Flow cytometry and light microscopy
were used to confirm the maturation of DC in response
to each reagent tested.
Results showed that recombinant 15 000 MW gran-
ulysin was capable of maturation of immature DC
(Fig. 4). Expression of CD80 and HLA-DR, classical
markers of maturation, increased significantly on cells fol-
lowing culture in the presence of recombinant 15 000
MW granulysin, and the mean fluorescence intensity
observed was comparable to that seen following culture
with the positive control of LPS. Additionally, expression
of chemokine receptor CCR5, often expressed by imma-
ture, but not mature, DC, decreased following culture
with both reagents. Conversely, expression of CCR7, the
lymph node homing chemokine associated with matura-
tion, increased. The expression of CD14 and CCR2 on
DC before and after maturation was also determined, and
did not alter (not shown).
Taken together, these findings suggest that recombinant
15 000 MW granulysin is capable of causing maturation
of DC.
Recombinant 15 000 MW granulysin can induce
concentration-dependent migration of immature and
mature DC
As we had determined that 15 000 MW granulysin was
capable of causing the maturation of immature DC, we
next investigated if 15 000 MW granulysin could also
cause migration of immature or mature DC. Previous lit-
erature has shown that 10 nM recombinant 15 000 MW
granulysin can cause the migration of several immune cell
populations, including DC.16,17 We therefore sought to
Figure 3. Vd2+ cd T cells release granulysin in response to tumour. (a) The expression of exhaustion markers PD-1 and Lag-3 on, and the secre-
tion of granulysin by, Vd2+ cd T cells during the 9-day expansion process. (b) The percentage of Vd2+ cd T cells to express early activation mar-
ker CD69 following 24, 48 or 72 hr of culture with Daudi cells, Raji cells or Raji cells pre-treated for 24 hr with 5 lM zoledronic acid (ZA), as
determined by flow cytometry. (c) The concentration of interferon-c (IFN-c) found within supernatants taken from 24, 48 or 72 hr co-culture of
Vd2+ cd T cells with tumour cell lines, as determined by ELISA. (d) The percentage of Vd2+ cd T cells to express degranulation marker CD107a
following 24, 48 or 72 hr of culture with Daudi cells, Raji cells or Raji cells pre-treated for 24 hr with 5 lM ZA, as determined by flow cytometry.
(e) The concentration of granulysin found within supernatants taken from 24, 48 or 72 hr co-culture of Vd2+ cd T cells with tumour cell lines,
as determined by ELISA. (f) The concentration of granzyme B found within supernatants taken from 24, 48 or 72 hr co-culture of Vd2+ cd T
cells with tumour cell lines, as determined by ELISA. (g) Percentage killing of tumour cells by Vd2+ cd T cells following 24, 48 and 72 hr of cul-
ture, as determined by flow cytometry. Data shown are from six independent experiments, using Vd2+ cd T cells from six individual donors, with
error bars (SD). Differences between groups were assessed by two-way analysis of variance comparing negative control (Vd2+ cd T cells alone)
with all other groups. *P < 005. **P < 001. ***P < 0001. ****P < 00001.
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replicate DC migration in response to 10 nM recombinant
15 000 MW granulysin, and additionally tested migration
in response to a higher concentration of 66 nM recombi-
nant 15 000 MW granulysin. Ibidi l-migration assays and
time-lapse microscopy were used to follow the migration
patterns of cells in response to each stimulus for 24 hr.
Figure S3 (see Supplementary material) provides detailed
methodology for determination of percentage migration
in response to a stimulus. Recombinant RANTES was
used as a positive control of migration for immature DC,
and recombinant CCL19 was used as a positive control of
migration for mature DC. Concentrations used for posi-
tive controls were based on manufacturer’s recommenda-
tion.
In keeping with results obtained by Deng et al.,16 we
found that although immature DC did not migrate in
response to 10 nM recombinant 15 000 MW granulysin,
this concentration of granulysin caused marked migration
of mature DC (Fig. 5a,b). Interestingly, when the concen-
tration of recombinant 15 000 MW granulysin was
increased to 66 nM, mature DC no longer migrated
towards this reagent, and in fact the percentage migration
of these cells was determined to be less than that seen in
response to the negative control of medium alone, indi-
cating a movement away from this concentration of gran-
ulysin (Fig. 5c). In contrast, immature DC were found to
migrate towards 66 nM recombinant 15 000 MW
granulysin (Fig. 5a), and percentage migration was found
to be comparable to the positive control of recombinant
RANTES.
Taken together, these data suggest that recombinant
15 000 MW granulysin can cause the migration of imma-
ture and mature DC. In addition, results suggest that
granulysin may differentially cause both migration and
repulsion of matured DC, dependent on the concentra-
tion of granulysin.
Discussion
The remit of this study was to determine whether Vd2+
cd T cells released granulysin in response to a tumour
target, and to investigate the functional consequences of
this response. In this paper, we present evidence that
Vd2+ cd T cells express granulysin intracellularly in a con-
stitutive manner, and release this molecule on culture
with the tumour cell lines Daudi and Raji, albeit to differ-
ing degrees. In addition, we show that 15 000 MW gran-
ulysin can cause the maturation of immature DC, and
further propose that 15 000 MW granulysin may have a
dual capacity to cause both the chemotaxis of immature
DC and the fugetaxis of mature DC, in a concentration-
dependent manner.
Often referred to as ‘the bridge between the innate and










































Figure 4. Granulysin can cause maturation of immature dendritic cells (DC). Changes in mean fluorescence intensity (MFI) of cell surface mark-
ers CD80, CCR7, CCR5 and HLA-DR on monocyte-derived immature DC following culture with 100 ng/ml lipopolysaccharide (LPS) or 66 nM
recombinant 15 000 MW granulysin), as determined by flow cytometry. Treatment of cells with medium alone was included as a negative con-
trol. Data shown are the average taken from six individual donors. Differences between groups were assessed by two-way analysis of variance
comparing negative controls (pre-maturation and medium alone) with all other groups. *P < 005. **P < 001.
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Vd2+ cd T cells possess properties of both innate and
adaptive immune cells. Despite being a relatively small
immune cell subset, Vd2+ cd T cells have been shown to
respond rapidly to tumour, due to their ability to recog-
nize targets without prior antigen processing and presen-
tation. In this way, Vd2+ cd T cells make a crucial
contribution to the immune response to cancer. In fact,
research by Gentles et al.29 into the association of infil-
trating immune cell subsets with prognostic outcomes
showed that cd T cells were ranked as the highest indica-
tor of a favourable outcome for 25 different malignancies
and 14 solid tumours. Additionally, several studies have
cited the involvement of Vd2+ cd T cells activated with
BCG in the regression of tumour. For example, Takeuchi
and colleagues determined that production of IL-17 by cd
T cells following BCG inoculation in bladder cancer was
responsible for the subsequent recruitment of neutrophils
required for an anti-tumour response.30 More recently,
























































Figure 5. Recombinant 15 000 MW granulysin causes differential migration of immature and mature dendritic cells (DC). (a) The migration of
immature DC in response to 10 or 66 nM recombinant 15 000 MW granulysin, as determined by Ibidi l-migration assays. 500 ng/ml recombi-
nant RANTES was used as a positive control of immature DC migration, while 2 ng/ml recombinant CCL19 was used as a negative control. (b)
The migration of mature DC in response to 10 or 66 nM recombinant 15 000 MW granulysin, as determined by Ibidi l-migration assays.
500 ng/ml recombinant RANTES was used as a negative control of mature DC migration, whereas 2 ng/ml recombinant CCL19 was used as a
positive control. Concentrations used for positive and negative controls were based on manufacturer’s recommendation. Data shown are from six
independent experiments using immature and lipopolysaccharide-matured DC differentiated from the monocytes of six individual donors, with
error bars (SD). Differences between groups were assessed using one-way analyses of variance. *P < 005. **P < 001. ***P < 0001. UN = un-
treated. GNLY = 15 000 MW granulysin.
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substantial Vd2+ cd T-cell infiltration has been identified
in metastatic melanoma lesions following intralesional
injection of BCG. Yang et al.31 observed an increase in
CXCL9, CXCL10 and CXCL11, in addition to increased
expression of butyrophilin 3A1 in these lesions following
treatment, which they hypothesized resulted in the attrac-
tion and subsequent activation of intralesional Vd2+ cd T
cells. Interestingly, injection of these lesions with BCG led
to a 50% regression in tumour size, which may be linked
to the increased number of responding Vd2+ cd T cells.31
This emerging correlation between positive cancer out-
comes and the presence of activated Vd2+ cd T cells led
us to further investigate the ways in which this cell popu-
lation could be activated to release cytotoxic molecules,
and the functional effects of this with regard to tumour
cell killing.
In this study, we show that cd T cells do not require a
stimulatory signal to express 15 000 MW granulysin
intracellularly, and only express 9000 MW granulysin to a
high level, at least in our hands, following BCG stimula-
tion. These findings show similarities of cd T cells with
both NK cells of the innate immune system, and CD8+
ab T cells of the adaptive immune system. NK cells have
been shown to express both isoforms of granulysin con-
stitutively, and CD8+ ab T cells have been shown to
express granulysin only 3–4 days after activation.22,32 We
also found that the percentage of Vd2+ cd T cells express-
ing each isoform of granulysin was comparable to that
observed within the cd T-cell population as a whole. The
presence of intracellular granulysin within this subpopula-
tion before recognition of tumour and subsequent activa-
tion may allow a more rapid release of granulysin into
the surrounding environment when activation of the cell
does occur.
Our findings within this study have confirmed previous
evidence that Vd2+ cd T cells can be activated by both
ZA and BCG, as long as additional immune cell popula-
tions are present.25,26 However, only activation of PBMC
with BCG was able to cause a change in the percentage of
Vd2+ cd T cells expressing granulysin. It is not surprising
that stimulation of Vd2+ cd T cells caused an increase in
the expression of 9000 MW granulysin only; this is the
cytotoxic isoform of granulysin, which has been shown to
increase within other T-cell populations following activa-
tion.32 Interestingly, previous studies have shown an
increase in the expression of granulysin within popula-
tions of CD8+ ab T cells and CD4+ ab T cells following
BCG vaccination of neonates, so it is perhaps not unex-
pected that this effect is also seen in populations of Vd2+
cd T cells.33 However, a significant increase in intracellu-
lar 9000 MW granulysin expression was not observed fol-
lowing stimulation of Vd2+ cd T cells with ZA. This
could be a result of differences in the efficacy of IPP pro-
duced in response to ZA, and HMBPP produced by BCG
infection.8 Alternatively, the stimulation of PBMC with
BCG has been shown to cause activation of other popula-
tions of immune cells.34,35 This activation may deliver a
co-stimulatory signal to Vd2+ cd T cells, which is neces-
sary for the up-regulation of 9000 MW granulysin within
these cells, and which is not delivered following stimula-
tion with ZA, and highlights the requirement for other
immune cell populations in the activation of Vd2+ cd T
cells in response to these reagents.
For this reason, we sought to confirm that isolated
Vd2+ cd T cells could release granulysin in response to
tumour without additional activation. We showed that
in vitro, Vd2+ cd T cells released substantial amounts of
granulysin in response to culture with Daudi tumour
cells, known to be sensitive to Vd2+ cd T-cell killing, and
that they could also release this molecule, albeit to a les-
ser degree, in response to Raji cells (resistant to Vd2+ cd
T-cell killing) and Raji cells pre-treated with ZA. It is
interesting to note that although co-culture caused an
increase in the production of the cytotoxic molecule
granulysin by Vd2+ cd T cells, production of the classical
cytotoxic cytokine IFN-c remained low over all condi-
tions. This is in contrast to previous evidence, which
shows that Vd2+ cd T cells express IFN-c following acti-
vation, and that Vd2+ cd T cells deficient in IFN-c are
less likely to be able to kill tumour.36,37 A potential expla-
nation for this finding is that both Daudi and Raji cells
express receptors for IFN-c, suggesting that any IFN-c
released by Vd2+ cd T cells in response to tumour may
be taken up by the tumour cells themselves, and as such
will not be present within supernatants to be detected by
ELISA.38,39 The fact that the highest concentrations of
IFN-c detected by ELISA were found within supernatants
taken from the co-cultures of Vd2+ cd T cells with Daudi
cells suggests an excess of IFN-c produced by Vd2+ cd T
cells that cannot be taken up by the Daudi cells.
It is interesting that the pre-treatment of Raji cells with
ZA did not increase the release of granulysin to a level
comparable to that seen following culture of Vd2+ cd T
cells with Daudi cells, despite increasing the amount of
tumour cell death. The addition of ZA to Raji cells has
been previously shown to cause an increase in IPP expres-
sion, and so an increase in Vd2+ cd T-cell cytotoxicity. It
is possible that too low a concentration of ZA was used
in the experiments detailed here. Although we used 5 µM
ZA to induce sensitization of Raji cells to Vd2+ cd T-cell
killing, previous evidence by Idrees et al. has shown that
inhibition of farnesyl pyrophosphate synthase was not
observed within Raji cells until a concentration of 1 mM
ZA was added to cells in vitro. In addition, cytotoxicity of
Vd2+ cd T cells, as characterized by production of
tumour necrosis factor-a, was also not observed below
this concentration of ZA.40 Despite this, our data suggest
that granulysin may be released by Vd2+ cd T cells that
infiltrate and recognize tumours in vivo, which are sensi-
tive to killing by this cell type.
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We next investigated the role of granulysin in the matu-
ration of DC, and showed that recombinant 15 000 MW
granulysin was capable of causing the maturation of imma-
ture DC in a manner similar to that seen in response to
recombinant LPS. Granulysin has been described as an
immune alarmin,17 and several other alarmins have been
shown to cause the maturation of immature DC. For exam-
ple, research by Dumitriu et al.41 showed that high mobility
group box 1 caused maturation of DC, characterized by an
increase in expression of CCR7. We found that high con-
centrations of recombinant 15 000 MW granulysin were
also able to cause migration of immature DC. This is of
interest as it suggests that in a physiological setting, gran-
ulysin released by Vd2+ cd T cells in response to a tumour
target may contribute to the influx of immature DC to the
tumour site. However, perhaps more noteworthy is the
observation that recombinant 15 000 MW granulysin
appears to cause both the chemotaxis and fugetaxis of
matured DC dependent on concentration. Low concentra-
tions of granulysin were found to cause a marked migra-
tion of mature DC, whereas high concentrations of
granulysin induced a movement of these cells away from
this molecule. Research has shown evidence of this phe-
nomenon previously. Tharp determined that whether a
neutrophil migrated towards or away from IL-8 was depen-
dent on the absolute concentration of this molecule.42
Using microfluidic linear gradient generators and time-
lapse microscopy, results showed that at concentrations of
120 nM, neutrophils were seen to migrate towards IL-8,
whereas at concentrations of 12 lM, neutrophils displayed
potent fugetaxis.42 A similar phenomenon has been shown
for the ability of stromal cell derived factor (SDF) -1 to
cause the attraction and repulsion of T cells. At 100 ng/ml,
SDF-1 caused chemoattraction of both naive and memory
CD4+ and CD8+ ab T cells, whereas higher concentrations
of 10 lg/ml SDF-1 caused repulsion of these cells.43
To further assess the contribution of granulysin released
by Vd2+ cd T cells in response to tumour in the maturation
and migration of DC, it would be important to next deter-
mine whether we could replicate our findings using super-
natants taken from the co-culture of these cells with
tumour targets. We have conducted preliminary experi-
ments and observed that supernatants taken from the co-
culture of Vd2+ cd T cells and Daudi cells could effectively
induce both maturation of immature DC, and the migra-
tion of these cells towards the supernatant source (see Sup-
plementary material, Figs S4 and S5A). Interestingly, we
were also able to replicate the differential migration of
mature DC towards or away from granulysin, depending
on the concentration of this molecule present in the super-
natants tested. As can be seen from Fig. S5B (see Supple-
mentary material), mature DC migrated towards
supernatants taken from the co-culture of Vd2+ cd T cells
with Raji cells, which contained low concentrations of
granulysin (an average of 485 ng/ml). However, these cells
migrated away from supernatants taken from the co-cul-
ture of Vd2+ cd T cells with Daudi cells, containing higher
concentrations of this molecule (an average of 2860 ng/
ml). The inclusion of a granulysin blocking antibody,
before the addition of the supernatants to cultures of DC,
would allow definitive confirmation of the involvement of
15 000 MW granulysin in the effects observed, and this
would form the basis of future work.
Our data suggest that Vd2+ cd T cells, through the pro-
duction and release of granulysin, may be involved in
orchestrating adaptive immunity against tumour.
Through the release of granulysin, this cell population
may contribute to the arrival of immature DC popula-
tions to a site of tumour, and may then further con-
tribute to the migration of matured DC away from the
tumour site, and towards lymph nodes to activate the
adaptive immune response. We believe this to be an
interesting facet of the anti-tumour response of Vd2+ cd
T cells, and therefore worthy of further investigation.
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Figure S1. Representative gating strategy used to deter-
mine purity of isolated Vd2+ cd T cells.
Figure S2. Representative gating strategy used to estab-
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Figure S3. Example l-migration assay analysis.
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cause maturation of immature dendritic cells.
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